Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GlaxoSmithKline (LSE:GSK; GSK) announced two deals on Monday, partnering with OncoMed to develop antibodies targeting cancer stem cells and with Galapagos to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury